Differential regulation of noxa in normal Melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications

Fernandez, Y., Verhaegen, M., Miller, T. P., Rush, J. L., Steiner, P., Opipari, A. W., Lowe, S. W., Soengas, M. S. (July 2005) Differential regulation of noxa in normal Melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications. Cancer Research, 65 (14). pp. 6294-6304. ISSN 0008-5472

URL: https://www.ncbi.nlm.nih.gov/pubmed/16024631
DOI: 10.1158/0008-5472.CAN-05-0686

Abstract

Melanoma is the most aggressive form of skin cancer and advanced stages are invariably resistant to conventional therapeutic agents. Using bortezomib as a prototypic proteasome inhibitor, we have identified a novel and critical role of the proteasome in the maintenance of the malignant phenotype of melanoma cells that could have direct translational implications. Thus, melanoma cells from early, intermediate, and late stages of the disease could not sustain proteasome inhibition and underwent an effective activation of caspase-dependent and -independent death programs. This effect was tumor cell selective, because under similar conditions, normal melanocytes remained viable. Intriguingly, and despite of interfering with a cellular machinery in charge of controlling the half-life of the vast majority of cellular proteins, bortezomib did not promote a generalized disruption of melanoma-associated survival factors (including NF-kappa B, Bcl-2, Bcl-X-L, XIAP, TRAF-2, or FLIP). Instead, we identified a dramatic induction in vitro and in vivo of the BH3-only protein Noxa in melanoma cells (but not in normal melanocytes) in response to proteasome inhibition. RNA interference validated a critical role of Noxa for the cytotoxic effect of bortezomib. Notably, the proteasome-dependent regulation of Noxa was found to extend to other tumor types, and it could not be recapitulated by standard chemotherapeutic drugs. In summary, our results revealed Noxa as a new biomarker to gauge the efficacy of bortezomib specifically in tumor cells, and provide a new strategy to overcome tumor chemoresistance.

Item Type: Paper
Uncontrolled Keywords: MALIGNANT-MELANOMA malignant melanoma METASTATIC MELANOMA metastatic melanoma MEDIATED APOPTOSIS mediated apoptosis MULTIPLE-MYELOMA multiple myeloma DRUG-RESISTANCE drug resistance CANCER-CELLS CYCLE ARREST cycle arrest EXPRESSION expression PS-341 BORTEZOMIB bortezomib
Subjects: diseases & disorders > cancer
therapies
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Lowe lab
Depositing User: CSHL Librarian
Date: July 2005
Date Deposited: 13 Jan 2012 17:28
Last Modified: 03 May 2018 16:01
Related URLs:
URI: http://repository.cshl.edu/id/eprint/22567

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving